Iboga (Tabernanthe iboga)

Iboga (Tabernanthe iboga) is a West African shrub containing the psychoactive alkaloid ibogaine, traditionally used in Bwiti spiritual ceremonies. The plant affects multiple neurotransmitter systems including dopamine, serotonin, and NMDA receptors, producing profound psychoactive effects.

Origin & History

Iboga (Tabernanthe iboga) is a perennial rainforest shrub native to Central and West Africa, particularly Gabon and Cameroon, belonging to the Apocynaceae family. The primary source is the root bark, from which iboga alkaloids are extracted via solvent methods or as total alkaloid (TA) extracts containing up to 15% alkaloids.

Historical & Cultural Context

Iboga has been used for centuries in the Bwiti religion of Gabon and neighboring regions, primarily in initiatory rites for spiritual visions and introspection. Root bark is consumed in high doses for hallucinogenic/oneirogenic effects in rituals and as a stimulant for hunting stamina.

Health Benefits

• Traditional spiritual and introspective properties - used for centuries in Bwiti religion for initiatory rites (traditional evidence only)
• Potential stimulant effects - traditionally used for hunting stamina (traditional evidence only)
• No clinical trials or RCTs available in the research dossier to support specific health benefits
• Forensic detection studies exist but provide no therapeutic evidence
• Further clinical research needed to establish health benefits

How It Works

Ibogaine, the primary alkaloid in iboga, acts as an antagonist at NMDA receptors and inhibits serotonin transporter function. It also modulates dopaminergic pathways in the brain's reward system and affects nicotinic acetylcholine receptors. These multi-receptor interactions contribute to its profound psychoactive and potentially therapeutic neurological effects.

Scientific Research

The research dossier provides no details on human clinical trials, RCTs, or meta-analyses for iboga or its alkaloids. Limited forensic data notes ibogaine and metabolite noribogaine detection in tissues post-administration via LC-MS, but this is not clinical trial evidence. No PubMed PMIDs for therapeutic studies are mentioned.

Clinical Summary

No clinical trials or randomized controlled studies have been conducted specifically on whole iboga root preparations. Most research focuses on isolated ibogaine rather than the complete plant extract. Traditional use evidence comes from ethnobotanical studies of Bwiti practitioners in Gabon and Cameroon, but lacks quantified dosing or standardized outcome measures. The absence of clinical data makes it impossible to verify traditional claims or establish safety profiles.

Nutritional Profile

{"macronutrients": {"carbohydrates": "Not well-documented", "proteins": "Not well-documented", "fats": "Not well-documented"}, "micronutrients": {"vitamins": "Not well-documented", "minerals": "Not well-documented"}, "bioactive_compounds": {"ibogaine": "Approximately 6% of the dry weight of the root bark", "tabernanthine": "Present in trace amounts", "voacangine": "Present in trace amounts"}, "bioavailability_notes": "The bioavailability of ibogaine and other alkaloids is subject to significant first-pass metabolism, and their absorption can vary widely among individuals."}

Preparation & Dosage

No clinically studied dosage ranges are available in the research. Ibogaine comprises ~80% of total alkaloid extracts, with ibogaline up to 15% and ibogamine up to 5%. Semi-synthetic ibogaine HCl is produced from voacangine, but no standardization or dosing from studies is specified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Not applicable - no synergistic ingredients identified in research

Safety & Interactions

Iboga contains potent psychoactive compounds that can cause severe adverse effects including cardiac arrhythmias, seizures, and psychological distress. The plant is illegal in many countries due to its ibogaine content and associated fatalities. It should never be combined with other medications, particularly those affecting heart rhythm or central nervous system function. Pregnant and breastfeeding women should avoid iboga completely due to unknown but potentially severe developmental risks.